Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...

Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a study titled ‘Prospective ...

After six months of treatment, medicines called 'biologics' seem to work best to clear raised patches of psoriasis on the skin. Longer studies are needed to assess the benefits and potential unwanted ...

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Risankizumab also showed superiority compared to ustekinumab in all secondary endpoints: Clinical remission at 48 weeks occurred in 61% of risankizumab patients and 41% of ustekinumab patients (P ...

AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis PRESS RELEASE – For UK consumer health, medical and ...

Risankizumab appears to be more effective than ustekinumab in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease.

The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn’s disease are unknown. In this phase 3b, multicenter, open-label, randomized, controlled trial with ...